|
|
|
|
Todd M. Fruchterman
Kinetic Concepts (KCI ) |
2008 Annual Comp.
|
|
$1,563,712
$743,372
$1,375,885
|
|
 |
Base Salary |
$344,500 |
| Cash Bonus |
$228,728 |
|
Stock Gains
Stock Expense
Stock Granted
|
$514,913
$169,484
$274,069
|
|
Options Gains
Options Expense
Options Granted
|
$474,911
$0
$527,928
|
| Other |
$660 |
| |
|
FYE 12/31/2008 |
|
|
|
Biography
Todd M. Fruchterman, M.D., Ph.D. joined KCI in July 2006 as Senior Vice President, Research & Development. In March 2007, Dr. Fruchterman was appointed Chief Technology Officer in addition to his role as Senior Vice President, Research and Development and in February 2009 was appointed Chief Medical Officer as well. Prior to joining KCI, Dr. Fruchterman served in a number of roles for Johnson & Johnson, where he most recently was responsible for the worldwide biosurgical development portfolio and directed worldwide biosurgical research and development for Johnson & Johnson's Ethicon division. Prior to Johnson & Johnson, from June 2003 to July 2004, Dr. Fruchterman directed medical and strategic marketing at Schering-Plough Corporation for the worldwide hepatitis business. From May 2000 to March 2003, Dr. Fruchterman worked for Response Genetics, Inc., where, during his tenure, he held positions of President, Chief Executive Officer, and Chief Operating Officer.
| Board Memberships |  | N/A | | Former Named Executive Positions | | N/A | | Former Board Affiliations | | N/A |
|
|
|
Accumulated Wealth
|
|
Total |
$419,658 |
|
Equity Holdings |
$419,658 |
|
Pension Balance |
$0 |
|
Deferred Comp. Balance |
$0 |
|
